EMA Reviews Meningioma Risk With Cyproterone Medicines

The European Medicines Agency is looking into the magnitude of meningioma risk with high doses of cyproterone medicines. 

SideEffects
The EMA Has Initiated A Safety Review Of Cyproterone Medicines • Source: Shutterstock

The European Medicines Agency's pharmacovigilance committee, the PRAC, has launched a review to examine whether changes should be made to the labeling of cyproterone-containing medicines to warn patients about the risk of meningioma at high doses.

Cyproterone is a progesterone derivative with anti-androgenic properties and is used to treat a wide range of conditions – including...

More from Europe

More from Geography